Host: Sara M. Tolaney, MD, MPH This Chairpersons Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best

Host: Christina Economides, MD Guest: Brian Howard, MD Guest: David N. Kenigsberg, MD, FACC Despite guideline-directed medical therapy, many patients with heart failure will continue to develop worsening symptoms and diminishing quality

Host: Amir T. Fathi, MD Guest: Courtney DiNardo, MD Guest: Brian A. Jonas, MD, PhD While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and individualize care, the comple

Host: Matthew S. Davids, MD, MMSc This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial prac

Host: Caroline Piatek, MD Guest: Irina Murakhovskaya, MD Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37oC. Innovative

Host: Helena Yu, MD The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findin

Host: Shubham Pant, MD, MBBS Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical

Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants wi

Host: Shubham Pant, MD, MBBS This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants

Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants wi